661 abstracts found.



Results filter

Multi-parameter flow cytometry immune profiling of head and neck and salivary gland cancers.

Year:

Session type:

Rizwana Sharmin Rahman1,Gareth Howell1,Anupam Goenka1,Emma Connolly1,Christopher Jagger1,Guy Betts2,Jarrod Homer2,Tracy Hussell1,Robert Metcalf1
1University of Manchester,2Manchester University NHS Foundation Trust

Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK

Year:

Session type:

Robert Watson1,Hugo De La Peña1,Maria Tsakok1,William Halliwell1,Johnson Joseph1,Sara Stoneham2,Jonathan Shamash3,Johnathan Joffe4,Danish Mazhar5,Ling Pei Ho1,Zoe Traill6,Sue Brand7,Andrew Protheroe1
1University of Oxford,2University College London Hospitials NHS Foundation Trust,3Barts Health NHS Trust,4Calderdale & Huddersfield NHS Foundation Trust,5Cambridge University Hospitals NHS Foundation Trust,6Oxford University NHS Foundation Trust,7University Hospitals Bristol

Bone Metastasis Inadequately Assessed by CT in Women with Breast Cancer

Year:

Session type:

Keng Sam Wu1,Sacha Jon Howell1
1The Christie NHS Foundation Trust

The development of early warning diagnostic and treatment response markers of high grade serous carcinomas of the ovary/fallopian tube.

Year:

Session type:

Laura Feeney1,Sharon Eddie Parkinson2,Darren McArt2,Niamh O'Brien2,Ken Mills2,Manuel Salto-Tellez2,Richard Kennedy2,James Beirne2,Paul Mullan2
1CCRCB Queens University Belfast,2Queens University Belfast

Predicting Drug Response in Cancer in Cancer Cell Lines using Deep Learning for precision treatments

Year:

Session type:

Jyothi Deva datta reddy1,Dr.ram Reddy2,Samyukta Reddy3
1Cancer moonshot @ www.cancermoonshot.in,2Care cancer center,3CancerMoonshot

C-terminal tensin-like (CTEN) ability to induce cell migration is independent of its interaction with β-catenin in colorectal cancer cell line

Year:

Session type:

Abdulaziz Alfahed1,Teresa Raposo1,Mohammad Ilyas1
1Molecular Pathology Group and Nottingham Molecular Pathology Node, School of Medicine, University of Nottingham

The challenge of PD-L1 clinical testing in NSCLC: current standards, sampling considerations and a future opportunity for RNAScope and digital pathology?

Year:

Session type:

Matthew Humphries1,Stephen McQuaid1,Stephanie Craig1,Victoria Bingham1,Perry Maxwell1,Manisha Maurya1,Fiona McLean1,James Sampson1,Patricia Higgins1,Christine Green1,Jacqueline James1,Manuel Salto-Tellez1
1Queens University Belfast

Legumain (LGMN) Regulation of Advanced Prostate Cancer via HSD17B4

Year:

Session type:

Alice Ormrod1,Sharon Eddie1,Richard Williams1,Paul Mullan1
1Queen's University Belfast

Studying Rac1b function in colorectal cancer

Year:

Session type:

Victoria Gudiño1,Caroline Billard1,Patrizia Cammareri1,Alex Von Kriegsheim1,Noor Gammoh1,Stuart Aitken2,John Cassidy3,Colin Nixon4,Joanne Edwards4,Graeme Murray5,Owen Sansom4,Kevin Myant1
1Cancer Research UK Edinburgh Centre,2MRC University Unit for Human Genetics,3Cancer Research UK Cambridge Institute,4Beatson Institute for Cancer Research,5University of Aberdeen

T-oligo mediates DNA damage responses by modulating telomere associated proteins and telomerase

Year:

Session type:

Zachary Schrank1,Nabiha Khan1,Joseph Kellen1,Sanjana Singh1,Chike Osude1,Neelu Puri1
1UIC College of Medicine Rockford

Vismodegib for the treatment of locally advanced BCC – The East of England experience

Year:

Session type:

David Maskell1,Dr Stephanie Browne2,Jenny Nobes2,Marc Moncrieff2,Amer Durrani3,Kate Fife3
1NHS,2Norfolk and Norwich University Hospital Foundation Trust,3Cambridge University Hospitals

MMP9 circulating levels and promoter polymorphism in risk prediction of breast cancer

Year:

Session type:

Farhad Mashayekhi1,Farbod Bahreini2
1University of Guilan, Rasht,2University of Guilan, Iran

MAMMO-50: Mammographic surveillance in breast cancer patients over 50 years of age.

Year:

Session type:

Janet Dunn1,Andy Evans2,Anthony Maxwell3,Andrea Marshall1,Maria Ramirez1,Annie Young4,Eila Watson5,Maggie Wilcox6,Sophie Gasson1,Helen Higgins1,Sarah Pinder7,Peter Donnelly8
1Warwick Clinical Trials Unit,2Ninewells Medical School,3University Hospital South Manchester NHS Foundation Trust,4,5Oxford Brookes University,6Independent Cancer Patient Voices,7Division of Cancer Studies, Kings College,8South Devon Healthcare NHS

The molecular mechanism behind PD-L1 upregulation upon 5-fluorouracil treatment in colorectal cancer cells

Year:

Session type:

Tamas Sessler1,Fiammetta Falcone2,Timothy Wright2,Peter Gallagher2,Daniel Longley3,Simon McDade2
1DRG/FGG QUB,2FGG QUB,3DRG QUB

A high-throughput in vitro screen for inhibitors of myeloid derived suppressor cells (MDSC) to improve immunotherapy of cancer

Year:

Session type:

Jennifer Frosch1,Lucia Gargiulo1,Cita Hanif Mufihah1,John Anderson2
1UCL Great Ormond Street Institute of Child Health,2Institute of Child Health, UCL

METASTATIC DISEASE REPRESENTATION- AN ANALYSIS OF 148 PAIRED COLORECTAL CANCER LYMPH NODE METASTATIC TUMOUR DEPOSITS

Year:

Session type:

Thomas Starkey1,Tessa Sandberg2,Ian Tomlinson2,Lennard YW Lee2
1,2Institute of Cancer Sciences, University of Birmingham

An evaluation of Personal and Public Involvement (PPI) in Cancer Research in Northern Ireland – What Next?

Year:

Session type:

Ruth Boyd1,Margaret Grayson2,Sandra McCarry3,Gail Johnston4
1NI Cancer Trials Network, Belfast HSC Trust, NI Cancer Research Consumer Forum,2NI Cancer Research Consumer Forum,3Belfast HSC Trust,4HSC R&D Division, Public Health Agency

Investigating the Interplay between Wilms’ Tumour 1 Protein and DNA Demethylation in Brain Tumours

Year:

Session type:

Ashley Ramsawhook1,Ashley Ramsawhook1
1University of Nottingham

Single cell copy number variation analysis (CNV) of circulating tumour cells (CTCs) in neuroendocrine tumour (NET) patients

Year:

Session type:

Alexa Childs1,Clare Vesely1,Francesca Rizzo1,Leah Ensell1,Helen Lowe1,Christina Thirlwell1,Christos Toumpanakis2,Martyn Caplin2,John Hartley1,Tim Meyer1
1UCL Cancer Institute,2Royal Free Hospital, London

Independent validation of the PREDICT breast cancer prognostication and treatment benefit prediction tool using data from the Scottish cancer registry

Year:

Session type:

Ewan Gray1,Joachim Marti2,David Brewster1,Jeremy Wyatt3,Peter Hall1
1University of Edinburgh,2University of Lausanne,3University of Southapmton

Investigation of transglutaminase 2 as a biomarker of invasive breast cancer that is likely to metastasise

Year:

Session type:

Fiona Blows1,Elena Provenzano2,Raza Ali3,Wei Cope4,Paul Pharoah4,Claire Pike5,Peter Coussons5
1Anglia Ruskin University and University of Cambridge,2Addenbrooke's Hospital,3University of Cambridge and University of Zurich,4University of Cambridge,5Anglia Ruskin University

12 week PET-CT scans post-radiotherapy for Human Papillomavirus (HPV) positive Oropharygeal Squamous Cell Cancers (OPSCC) have low positive predictive value (PPV) for lymph node (LN) residual disease

Year:

Session type:

Robert Rulach1,Suyun Zhou1,Fraser Hendry2,David Stobo2,Mary Frances Dempsey2,Derek Grose1,Carolynn Lamb1,Allan James1,Stefano Schipani1,Christina Wilson1,Mohammed Rizwanullah1,Claire Paterson1
1The Beatson West of Scotland Cancer Centre,2NHS Greater Glasgow and Clyde

Glyoxalase 1 overexpression associated multidrug resistance in cancer chemotherapy

Year:

Session type:

Hafsa Abbas1,Dr Mingzhan Xue1,Dr Naila Rabbani1,Professor Paul Thornalley1
1University of Warwick

Real-World Treatment Patterns and Clinical Outcomes in Advanced/Metastatic NSCLC Patients in England

Year:

Session type:

Katharina Verleger1,Nadine Hertel2,Caitlyn Solem1,John R Penrod2,Cynthia Macahilig3,Linlin Luo1,S. Michael Crawford4
1Pharmerit International,2Bristol-Myers Squibb,3Medical Data Analytics,4Airedale NHS Foundation Trust

Identifying and counting people living with treatable but not curable cancer in the England cancer registry

Year:

Session type:

Rachel White1,Joanna Pethick2,Archie Macnair3,Gregory Fallica1,Jennifer Than4,Jane Maher1
1Macmillan Cancer Support,2National Cancer Registration and Analysis Service, Public Health England,3Macmillan Cancer Support & The Royal College of Radiologists ,4Macmillan Cancer Support & National Cancer Registration and Analysis Service, Public Health England

Living with and beyond colorectal cancer: ColoREctal Well-being (CREW) study at five years

Year:

Session type:

Claire Foster1,Sally Wheelwright1,Lynn Calman2,Samantha Sodergren1,Joanne Haviland3,Amanda Cummings1,Jane Winter4,Amy Din1,Deborah Fenlon5,Janis Baird1,Jessica Corner6,Alison Richardson4,Peter W Smith1,Study Advisory Committee Members1
1University of Southampton,2,3Institute of Cancer Research,4University of Southampton, University Hospital Southampton NHS Foundation Trust,5Swansea University,6University of Nottingham

Disulfiram reverses chemoresistance in pancreatic ductal adenocarcinoma (PDAC) by targeting hypoxia induced NF-KB pathway to eradicate cancer stem cell population

Year:

Session type:

Ogechi Nkeonye1,Ogechi Nkeonye1,Vinodh Kannappan1,Rajagopal Kilari1,Kate Butcher1,Karim Azar1,Mark Morris1,Christopher Heeschen2,Weiguang Wang1
1University of Wolverhampton,2Barts Cancer Institute

A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): A patient and health care professional consensus

Year:

Session type:

Rebecca Fish1,Caroline Sanders1,Richard Adams2,Julie Brewer3,Sara Brookes4,Jill DeNardo3,Rohit Kochhar3,Mark Saunders3,David Sebag-Montefiore5,Paula Williamson6,Andrew Renehan7
1University of Manchester,2Cardiff University School of Medicine,3The Christie NHS Foundation Trust,4University of Birmingham,5University of Leeds, Leeds Cancer Centre,6MRC North West Hub for Trials Methodology Research,7The University of Manchester

Progression free survival as a surrogate endpoint for overall survival in first-line therapy of advanced ovarian cancer: A Gynecologic Cancer InterGroup (GCIG) individual patient-level meta-analysis

Year:

Session type:

Rosalind Glasspool1,Liz-Anne Lewsley2,Gennaro Daniele3,Adrian David Cook4,Nozomu Yanaihara5,Anna Tinker6,Gunnar Kristensen7,Petronella Ottevanger8,Gerasimos Aravantinos9,Ingrid A. Boere10,Robert Fruscio11,Anna K.L. Reyners12,Eric Pujade-Lauraine13,Andrea Harkin2,Sandro Pignata14,Tatsuo Kagimura15,Stephen Welch16,Eleni, Karamouza17,Stan Kaye18,Timothy Perren19,Susana N Banerjee20,Xavier Paoletti21
1Beatson West of Scotland Cancer Centre,2Cancer Research UK Clinical Trials Unit, Institute of Cancer Research, University of Glasgow, Glasgow,,3Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”- IRCCS, Naples,4MRC Clinical Trials Unit at UCL, London,,5The Jikei University School of Medicine, Tokyo,6British Columbia Cancer Agency, Vancouver, BC,,7Norwegian Radium Hospital, Oslo,8Department of Medical Oncology, Radboud University Medical Center, Nijmegen,9Hellenic Cooperative Oncology Group (HeCOG), Athens,10Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam,11University of Milan & Bicocca San Gerardo Hospital, Monza,,12University Medical Center, University of Groningen, Groningen,,13Universite Paris-Descartes, AP-HP, Paris,,14National Cancer Institute of Naples, Naples,,15Foundation for Biomedical Research and Innovation, Translational Research Informatics Center, Kobe,,16London Regional Cancer Program, London, ON,,17Ligue Nationale Contre le Cancer Meta-Analysis Platform, Department of Biostatistics and Epidemiology, Gustave-Roussy Cancer Campus, Villejuif,,18The Institute of Cancer Research and The Royal Marsden Hospital, Sutton,19Leeds Teaching Hospitals NHS Trust, Leeds,20The Royal Marsden NHS Foundation Trust, London,,21Gustave Roussy Institute, Villejuif

European Cancer Incidence is Significantly Reduced in Huntington’s Disease Patients – Unravelling it’s Protective Mechanisms.

Year:

Session type:

Paul McNulty1,Raviram Ramesh1,Richard Pilcher1,Renata Neciunaite1,Lesley Jones1,Alys Hughes1,Daniel Farewell1,Timothy Stone1,Peter Holmes1

1Cardiff University


Pre-clinical models of glioblastoma that enable more accurate evaluation of new treatment combinations

Year:

Session type:

Anthony Chalmers1
1Glasgow Centre for Cancer Research

Identifying the early cancerous body

Year:

Session type:

Rikke Sand Anderson1
1Aarhus University

Identification of novel therapeutic targets for triple negative breast cancer through integrative kinomics

Year:

Session type:

Roger Daly1
1Department of Biochemistry and Molecular Biology, Monash University

Digital Pathology & Artificial Intelligence, the Third Revolution in Pathology

Year:

Session type:

Manuel Salto-Tellez1
1Queen's University Belfast

Designing trials in smaller populations

Year:

Session type:

Matthew Sydes1
1MRC Clinical Trials Unit at UCL

Rates of Symptomatic and Incidentally found Non Haematological Malignancies made in New Patients Referrals to the Haematology clinic over a 5 year period

Year:

Session type:

Andrew Fyfe1
1NHS Lanarkshire

Seizure Prophylaxis in Glioma (SPRING): A phase III randomised trial comparing prophylactic Levetiracetam versus no prophylactic anti-epileptic drug in  newly diagnosed presumed supratentorial glioma.

Year:

Session type:

Robin Grant1,Colin Watts2,Michael Jenkinson3,Luke Vale4,Tony Marson5,Robert Hill6,Tracy McEleny6
1NHS Lothian,2Department of Neurosurgery, University of Birmingham,3Department of Neurosurgery, Institute of Translational Medicine, University of Liverpool,4Institute of Health & Society Newcastle University Baddiley-Clark Building Richardson Road Newcastle upon Tyne,5Department of Neurology, Molecular and Clinical Pharmacology The Walton Centre NHS Foundation Trust University of Liverpool,6Scottish Clinical Trials Research Unit NHS National Services Scotland Gyle Square 1 South Gyle Crescent Edinburgh

Adjuvant FEC-D in Breast Cancer – 8 year follow-up real world data

Year:

Session type:

Mark Baxter1,Judith Fraser1
1Beatson West of Scotland Cancer Centre

Immune checkpoint inhibitors are effective and well tolerated in elderly patients

Year:

Session type:

Shuai Zhang1,Ali Abdulnabi Mohamed2,Amit Samani3,Laura Spiers4,Zayd Tippu5,Sophie Merrick6,Miranda Payne7,Guy Faust8,Sophie Papa9,Debra Josephs9
1University Hospitals of Leicester NHS Trust,2University Hospitals of Leicester NHS Trust and Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom,3Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom;,4Oxford University NHS Foundation Trust, Oxford, United Kingdom,5King’s College London, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom,6Guy's and St Thomas' NHS Foundation Trust and King's College London, London, GB,7Oxford Cancer Centre, Oxford, United Kingdom;,8University Hospitals of Leicester NHS Trust, Leicester, United Kingdom;,9Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK

Outcome of remission induction in childhood acute lymphoblastic leukemia treated with modified BFM-90 protocol and UKALL 2011 interim guidelines, Single Centre experience from Pakistan

Year:

Session type:

Safia Khan1,Muhammad Latif2,Mazin Sirelkhatim3,Faisal Azam2
1The Children's Hospital & ICH, Lahore,2king Fahad Specialist Hospital,3North Wales Cancer Treatment Centre

Clinicopathological and functional significance of meiotic recombination 11 (MRE11) in epithelial ovarian cancers: A target validation study.

Year:

Session type:

Adel Alblihy1,Alabdullah Alabdullah1,Reem Ali1,Michael Toss1,Katia Almeida Masquita Almeida Masquita1,Emad A Rakha Rakha1,Srinivasan Madhusudan1
1University of Nottingham

Primary concurrent chemoradiotherapy for locally advanced laryngeal squamous cell carcinoma

Year:

Session type:

Delali Adjogatse1,Francesca De Felice2,Yae-eun Suh3,Jean-Pierre Jeannon4,Richard Oakley4,Ricard Simo4,Mary Lei5,Teresa Guerrero Urbano5
1Guy's and St Thomas' NHS Foundation Trust,2Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome,3Department of Clinical Oncology, Royal Marsden Hospitals NHS Foundation Trust, London,4Head and Neck Unit, Guy's and St Thomas' NHS Foundation Trust, London,5Guy's Cancer Centre, Guy's and St Thomas' NHS Foundation Trust, London

Pathways to diagnosis of a second primary cancer: a qualitative interview study

Year:

Session type:

Christine Campbell1,Annemieke Bikker1,Lovney Kanguru1,Debbie Cavers1,Karen Barnett2,David Weller3,David Brewster1
1University of Edinburgh,2University of Dundee,3Univeristy of Edinburgh

Patient Reported Outcomes in cancer, impact of Age and Carer role demands associated with Treatment (PROACT): The ‘lucky’ construct

Year:

Session type:

Rachel Starkings1,Valerie Shilling1,Valerie Jenkins1,Lesley Fallowfield1
1SHORE-C, University of Sussex

Tumour Cell Morphometrics Predict Survival in Lung Adenocarcinoma

Year:

Session type:

Najah Alsubaie1,David Snead2,Nasir Rajpoot3
1Department of Computer Science, University of Warwick, UK. Department of Computer Science, Princess Nourah University, KSA,2Department of Pathology, University Hospitals Coventry and Warwickshire, UK,3Department of Computer Science, University of Warwick, UK. Department of Pathology, University Hospitals Coventry and Warwickshire, UK. The Alan Turing Institute, UK

The role of IKK-alpha in colorectal cancer

Year:

Session type:

Meera Patel1,Hannah Hood2,Jean Quinn3,Antonia Roseweir3,Arfon Powell4,Paul Horgan3,Donald McMcMillan3,Joanne Edwards1
1Institute of Cancer Sciences, University of Glasgow,2School of Medicine, University of Glasgow,3Academic Unit of Surgery, University of Glasgow,4School of Medicine, Cardiff University

Characterisation of CRISPR-induced RET gatekeeper cell line in a medullary thyroid carcinoma model

Year:

Session type:

Habiba Begum1,Mandy Watson1,Elizabeth Blaikley1,Graeme Walker1,Ian Waddell1,Donald Ogilvie1,Caroline Springer1
1Cancer Research UK Manchester Institute

Outcomes for advanced and metastatic testicular cancer patients treated with chemotherapy: Survival analysis based on type, stage, and IGCCCG prognostic score – a large single centre LTHTR experience

Year:

Session type:

Parth Desai1,Wiebke Appel2,Alison Birtle2
1Rosemere Cancer Foundation,2Rosemere Cancer Foundation, Royal Preston Hsopital

Identifying smoking-independent targets for lung cancer prevention: a systematic Mendelian randomization study

Year:

Session type:

Nabila Kazmi1,Kaitlin Wade1,Aayah Nounu1,Ryan Langdon1,Vanessa Tan1,James Yarmolinsky1,Jie Zheng1,Gibran Hemani1,Robert Torres2,Mattias Johansson2,Tom Gaunt1,Rayjean Hung3,Chris Amos4,Sarah Lewis1,Richard Martin1,Paul Brennan2,Caroline Relton1,George Smith1,Phili Haycock1
1University of Bristol,2International Agency for Research on Cancer (IARC),3Sinai Health System,4Baylor College of Medicine

Evaluation of Tumor/Tumor Microenvironment Interactions for Potential Predictors of Patient Response to Napabucasin

Year:

Session type:

Harry Rogoff1,An-Yun Chang1,Eric Hsu1,Jaimin Patel1,Minjie Zhang1,Haruhisa Iguchi1
1Boston Biomedical, Inc.